三唑类药物D0870在系统性组织胞浆菌病小鼠模型中的疗效。
Efficacy of the triazole D0870 in a murine model of systemic histoplasmosis.
作者信息
Clemons K V, Stevens D A
机构信息
Department of Medicine, Santa Clara Valley Medical Center, San Jose, California 95128, USA.
出版信息
Antimicrob Agents Chemother. 1995 Mar;39(3):778-80. doi: 10.1128/AAC.39.3.778.
Abstract
The efficacy of D0870 was studied in a murine model of systemic histoplasmosis and was compared with that of fluconazole. All regimens of D0870 (1 or 10 mg/kg of body weight given daily or 1, 10, or 100 mg/kg given every other day) and 100 mg of fluconazole per kg given daily provided complete protection from lethality. Comparison of the number of viable Histoplasma capsulatum yeasts remaining in the spleen or liver indicated that D0870 was superior to fluconazole in clearing and curing infection. D0870 was 10- to 100-fold more efficacious than fluconazole in the treatment of experimental histoplasmosis.
摘要
在系统性组织胞浆菌病的小鼠模型中研究了D0870的疗效，并与氟康唑进行了比较。D0870的所有给药方案（每日给予1或10mg/kg体重或隔日给予1、10或100mg/kg）以及每日给予每千克100mg氟康唑均可提供完全的致死保护。比较脾脏或肝脏中残留的荚膜组织胞浆菌酵母的活菌数量表明，D0870在清除和治愈感染方面优于氟康唑。在治疗实验性组织胞浆菌病方面，D0870的疗效比氟康唑高10至100倍。
相似文献
1
Efficacy of the triazole D0870 in a murine model of systemic histoplasmosis.三唑类药物D0870在系统性组织胞浆菌病小鼠模型中的疗效。
Antimicrob Agents Chemother. 1995 Mar;39(3):778-80. doi: 10.1128/AAC.39.3.778.
2
Therapy of systemic histoplasmosis in immunosuppressed mice with the triazole D0870.用三唑类药物D0870治疗免疫抑制小鼠的全身性组织胞浆菌病。
J Med Vet Mycol. 1996 Jul-Aug;34(4):241-6. doi: 10.1080/02681219680000411.
3
Utility of the triazole D0870 in the treatment of experimental systemic coccidioidomycosis.三唑类药物D0870在实验性系统性球孢子菌病治疗中的效用。
J Med Vet Mycol. 1994;32(4):323-6. doi: 10.1080/02681219480000411.
4
Efficacy of ravuconazole in treatment of systemic murine histoplasmosis.雷夫康唑治疗系统性小鼠组织胞浆菌病的疗效。
Antimicrob Agents Chemother. 2002 Mar;46(3):922-4. doi: 10.1128/AAC.46.3.922-924.2002.
5
Efficacy of D0870 treatment of experimental Candida vaginitis.D0870治疗实验性念珠菌性阴道炎的疗效
Antimicrob Agents Chemother. 1997 Jul;41(7):1455-9. doi: 10.1128/AAC.41.7.1455.
6
Fluconazole, D0870, and flucytosine treatment of disseminated Candida tropicalis infections in mice.氟康唑（D0870）与氟胞嘧啶对小鼠播散性热带念珠菌感染的治疗作用
Antimicrob Agents Chemother. 1995 Apr;39(4):924-9. doi: 10.1128/AAC.39.4.924.
7
In vitro and in vivo activities of Sch 39304, fluconazole, and amphotericin B against Histoplasma capsulatum.Sch 39304、氟康唑和两性霉素B对荚膜组织胞浆菌的体外及体内活性
Antimicrob Agents Chemother. 1990 Apr;34(4):524-8. doi: 10.1128/AAC.34.4.524.
8
Antifungal activity of D0870 against murine infections and its mechanism of action.D0870对小鼠感染的抗真菌活性及其作用机制。
Chemotherapy. 1998 Mar-Apr;44(2):112-20. doi: 10.1159/000007102.
9
Activities of the triazole D0870 in vitro and against murine blastomycosis.三唑类药物D0870的体外活性及对小鼠芽生菌病的作用
Antimicrob Agents Chemother. 1993 May;37(5):1177-9. doi: 10.1128/AAC.37.5.1177.
10
Comparison of a new triazole, posaconazole, with itraconazole and amphotericin B for treatment of histoplasmosis following pulmonary challenge in immunocompromised mice.新型三唑类药物泊沙康唑与伊曲康唑及两性霉素B在免疫功能低下小鼠肺部感染组织胞浆菌病后的治疗效果比较
Antimicrob Agents Chemother. 2000 Oct;44(10):2604-8. doi: 10.1128/AAC.44.10.2604-2608.2000.
引用本文的文献
1
Efficacy of ravuconazole in treatment of systemic murine histoplasmosis.雷夫康唑治疗系统性小鼠组织胞浆菌病的疗效。
Antimicrob Agents Chemother. 2002 Mar;46(3):922-4. doi: 10.1128/AAC.46.3.922-924.2002.
2
Murine models of blastomycosis, coccidioidomycosis, and histoplasmosis.芽生菌病、球孢子菌病和组织胞浆菌病的小鼠模型。
Mycopathologia. 1999;146(2):53-65. doi: 10.1023/a:1007081707287.
3
Comparison of a new triazole antifungal agent, Schering 56592, with itraconazole and amphotericin B for treatment of histoplasmosis in immunocompetent mice.一种新型三唑类抗真菌药物（先灵葆雅56592）与伊曲康唑和两性霉素B治疗免疫功能正常小鼠组织胞浆菌病的比较。
Antimicrob Agents Chemother. 1999 Feb;43(2):322-8. doi: 10.1128/AAC.43.2.322.
4
Efficacy of D0870 treatment of experimental Candida vaginitis.D0870治疗实验性念珠菌性阴道炎的疗效
Antimicrob Agents Chemother. 1997 Jul;41(7):1455-9. doi: 10.1128/AAC.41.7.1455.
本文引用的文献
1
Activities of the triazole D0870 in vitro and against murine blastomycosis.三唑类药物D0870的体外活性及对小鼠芽生菌病的作用
Antimicrob Agents Chemother. 1993 May;37(5):1177-9. doi: 10.1128/AAC.37.5.1177.
2
In vitro and in vivo antifungal activities of D0870, a new triazole agent.新型三唑类药物D0870的体外和体内抗真菌活性
Antimicrob Agents Chemother. 1993 Nov;37(11):2412-7. doi: 10.1128/AAC.37.11.2412.
3
In vitro studies of a new antifungal triazole, D0870, against Candida albicans, Cryptococcus neoformans, and other pathogenic yeasts.新型抗真菌三唑类药物D0870对白色念珠菌、新型隐球菌及其他致病性酵母的体外研究。
Antimicrob Agents Chemother. 1993 Oct;37(10):2126-31. doi: 10.1128/AAC.37.10.2126.
4
Utility of the triazole D0870 in the treatment of experimental systemic coccidioidomycosis.三唑类药物D0870在实验性系统性球孢子菌病治疗中的效用。
J Med Vet Mycol. 1994;32(4):323-6. doi: 10.1080/02681219480000411.
5
Histoplasmosis and AIDS.组织胞浆菌病与艾滋病
J Infect Dis. 1988 Sep;158(3):623-6. doi: 10.1093/infdis/158.3.623.
6
Treatment of murine histoplasmosis with UK 49,858 (fluconazole).用UK 49,858（氟康唑）治疗小鼠组织胞浆菌病。
Am Rev Respir Dis. 1986 Oct;134(4):768-70. doi: 10.1164/arrd.1986.134.4.768.
7
Comparison of fluconazole and amphotericin B in treating histoplasmosis in immunosuppressed mice.氟康唑与两性霉素B治疗免疫抑制小鼠组织胞浆菌病的比较。
Antimicrob Agents Chemother. 1987 Dec;31(12):2005-6. doi: 10.1128/AAC.31.12.2005.
8
In vitro and in vivo activities of Sch 39304, fluconazole, and amphotericin B against Histoplasma capsulatum.Sch 39304、氟康唑和两性霉素B对荚膜组织胞浆菌的体外及体内活性
Antimicrob Agents Chemother. 1990 Apr;34(4):524-8. doi: 10.1128/AAC.34.4.524.
9
A Pan-American 5-year study of fluconazole therapy for deep mycoses in the immunocompetent host. Pan-American Study Group.泛美地区针对免疫功能正常宿主深部真菌病氟康唑治疗的5年研究。泛美研究小组。
Clin Infect Dis. 1992 Mar;14 Suppl 1:S68-76. doi: 10.1093/clinids/14.supplement_1.s68.
10
Efficacy and safety of amphotericin B colloidal dispersion compared with those of amphotericin B deoxycholate suspension for treatment of disseminated murine cryptococcosis.两性霉素B胶体分散体与两性霉素B脱氧胆酸盐混悬液治疗小鼠播散性隐球菌病的疗效和安全性比较
Antimicrob Agents Chemother. 1992 Dec;36(12):2656-60. doi: 10.1128/AAC.36.12.2656.
Zotero 插件